Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia.

摘要: Cervical cancer is a leading cause of death among women globally, with 12,800 new cases and 4600 deaths in the US 2000 [547508], highlighting pressing need for novel prophylactic therapeutic strategies. Persistent infection high-risk strains genital human papillomavirus (HPV) causally associated appearance persistence anogenital dysplasia, including cervical dysplasia. Genomic DNA from HPV types 16, 18, 31, 33, 45 56 detected over 90% tumors worldwide, HPV-16 being by far most prevalent type contributing 50 to 55% total [945882]. has also been implicated malignant processes anus, penis, vulva oropharynx, -18 accounting approximately 70% anal cancers 30 40% vulva, penis oropharynx [948180]. The development occurs through serial progression cytological alterations distinguished increasing dysplasia accumulation genetic present precursor lesions known as intraepithelial neoplasia [958050]. Current treatment high-grade (grade 2 or 3), which dysplastic cells occupy third epidermis, restricted excisional ablative procedures (ie, loop electrosurgical excision procedure [LEEP] laser) that remove destroy tissue [958027]. Such have efficacy rates ranging 60 are often complications [958028]. Likewise, limited invasive highly toxic such radical hysterectomy, chemotherapy radiotherapy because lack superior alternatives. Although treatments currently accepted, these do not target natural history, results re-infections subsequent [958029]. Therefore there requirement strategies prevention [958031]. In last few years, vaccination common -18) become available under widely accepted rationale HPV-related will be precluded preventing primary infection. This strategy aimed at generating neutralizing antibodies L1 major capsid protein [945891]. However, immune-competent infected even spontaneously clear within only minority persistent develop fewer still progress